Ultragenyx Pharmaceutical Inc. Files 8-K
Ticker: RARE · Form: 8-K · Filed: Jun 27, 2025 · CIK: 1515673
| Field | Detail |
|---|---|
| Company | Ultragenyx Pharmaceutical Inc. (RARE) |
| Form Type | 8-K |
| Filed Date | Jun 27, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
Related Tickers: UGNX
TL;DR
UGNX filed an 8-K on 6/27. Details TBD.
AI Summary
Ultragenyx Pharmaceutical Inc. filed an 8-K on June 27, 2025, reporting an "Other Event." The filing does not contain specific details about the event, dollar amounts, or names beyond the company's standard information.
Why It Matters
This filing indicates a material event has occurred for Ultragenyx Pharmaceutical Inc., requiring disclosure to investors, though the specific nature of the event is not detailed in the provided text.
Risk Assessment
Risk Level: low — The filing is a standard 8-K current report with no specific financial or operational details provided in the excerpt, making it low risk.
Key Players & Entities
- Ultragenyx Pharmaceutical Inc. (company) — Registrant
- June 27, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 415-483-8800 (phone_number) — Registrant's Telephone Number
- 60 Leveroni Court (address) — Principal Executive Offices
- Novato, California (location) — Principal Executive Offices Location
FAQ
What is the exact nature of the "Other Event" reported by Ultragenyx Pharmaceutical Inc. on June 27, 2025?
The provided excerpt of the 8-K filing does not specify the details of the "Other Event."
Does the filing mention any financial transactions or agreements?
No, the provided text of the 8-K filing does not mention any specific financial transactions or agreements.
Are there any named individuals or new executive appointments mentioned in this filing?
The provided excerpt does not contain information about named individuals or executive appointments.
What is the Commission File Number for Ultragenyx Pharmaceutical Inc.?
The Commission File Number for Ultragenyx Pharmaceutical Inc. is 001-36276.
When is Ultragenyx Pharmaceutical Inc.'s fiscal year end?
Ultragenyx Pharmaceutical Inc.'s fiscal year ends on December 31 (1231).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 27, 2025 regarding Ultragenyx Pharmaceutical Inc. (RARE).